149 related articles for article (PubMed ID: 37145169)
1. ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma.
Jackson ER; Duchatel RJ; Staudt DE; Persson ML; Mannan A; Yadavilli S; Parackal S; Game S; Chong WC; Jayasekara WSN; Le Grand M; Kearney PS; Douglas AM; Findlay IJ; Germon ZP; McEwen HP; Beitaki TS; Patabendige A; Skerrett-Byrne DA; Nixon B; Smith ND; Day B; Manoharan N; Nagabushan S; Hansford JR; Govender D; McCowage GB; Firestein R; Howlett M; Endersby R; Gottardo NG; Alvaro F; Waszak SM; Larsen MR; Colino-Sanguino Y; Valdés-Mora F; Rakotomalala A; Meignan S; Pasquier E; Andre N; Hulleman E; Eisenstat DD; Vitanza NA; Nazarian J; Koschmann C; Mueller S; Cain JE; Dun MD
Cancer Res; 2023 May; 83(14):2421-37. PubMed ID: 37145169
[TBL] [Abstract][Full Text] [Related]
2. ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma.
Jackson ER; Duchatel RJ; Staudt DE; Persson ML; Mannan A; Yadavilli S; Parackal S; Game S; Chong WC; Jayasekara WSN; Grand ML; Kearney PS; Douglas AM; Findlay IJ; Germon ZP; McEwen HP; Beitaki TS; Patabendige A; Skerrett-Byrne DA; Nixon B; Smith ND; Day B; Manoharan N; Nagabushan S; Hansford JR; Govender D; McCowage GB; Firestein R; Howlett M; Endersby R; Gottardo NG; Alvaro F; Waszak SM; Larsen MR; Colino-Sanguino Y; Valdes-Mora F; Rakotomalala A; Meignan S; Pasquier E; André N; Hulleman E; Eisenstat DD; Vitanza NA; Nazarian J; Koschmann C; Mueller S; Cain JE; Dun MD
Cancer Res; 2023 May; ():OF1-OF17. PubMed ID: 37195023
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy.
Gardner SL; Tarapore RS; Allen J; McGovern SL; Zaky W; Odia Y; Daghistani D; Diaz Z; Hall MD; Khatib Z; Koschmann C; Cantor E; Kurokawa R; MacDonald TJ; Aguilera D; Vitanza NA; Mueller S; Kline C; Lu G; Allen JE; Khatua S
Neurooncol Adv; 2022; 4(1):vdac143. PubMed ID: 36382108
[TBL] [Abstract][Full Text] [Related]
4. Rational combination platform trial design for children and young adults with diffuse midline glioma: A report from PNOC.
Mueller S; Kline C; Franson A; van der Lugt J; Prados M; Waszak SM; Plasschaert SLA; Molinaro AM; Koschmann C; Nazarian J
Neuro Oncol; 2024 May; 26(Supplement_2):S125-S135. PubMed ID: 38124481
[TBL] [Abstract][Full Text] [Related]
5. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
Odia Y; Hall MD; Cloughesy TF; Wen PY; Arrillaga-Romany I; Daghistani D; Mehta MP; Tarapore RS; Ramage SC; Allen JE
Neuro Oncol; 2024 May; 26(Supplement_2):S165-S172. PubMed ID: 38386699
[TBL] [Abstract][Full Text] [Related]
6. First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report.
Hall MD; Odia Y; Allen JE; Tarapore R; Khatib Z; Niazi TN; Daghistani D; Schalop L; Chi AS; Oster W; Mehta MP
J Neurosurg Pediatr; 2019 Apr; 23(6):719-725. PubMed ID: 30952114
[TBL] [Abstract][Full Text] [Related]
7. Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas.
Przystal JM; Cianciolo Cosentino C; Yadavilli S; Zhang J; Laternser S; Bonner ER; Prasad R; Dawood AA; Lobeto N; Chin Chong W; Biery MC; Myers C; Olson JM; Panditharatna E; Kritzer B; Mourabit S; Vitanza NA; Filbin MG; de Iuliis GN; Dun MD; Koschmann C; Cain JE; Grotzer MA; Waszak SM; Mueller S; Nazarian J
Neuro Oncol; 2022 Sep; 24(9):1438-1451. PubMed ID: 35157764
[TBL] [Abstract][Full Text] [Related]
8. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
[TBL] [Abstract][Full Text] [Related]
9. A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered.
Jackson ER; Persson ML; Fish CJ; Findlay IJ; Mueller S; Nazarian J; Hulleman E; van der Lugt J; Duchatel RJ; Dun MD
Neuro Oncol; 2024 May; 26(Supplement_2):S136-S154. PubMed ID: 37589388
[TBL] [Abstract][Full Text] [Related]
10. PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma.
Duchatel RJ; Jackson ER; Parackal SG; Kiltschewskij D; Findlay IJ; Mannan A; Staudt DE; Thomas BC; Germon ZP; Laternser S; Kearney PS; Jamaluddin MFB; Douglas AM; Beitaki T; McEwen HP; Persson ML; Hocke EA; Jain V; Aksu M; Manning EE; Murray HC; Verrills NM; Sun CX; Daniel P; Vilain RE; Skerrett-Byrne DA; Nixon B; Hua S; de Bock CE; Colino-Sanguino Y; Valdes-Mora F; Tsoli M; Ziegler DS; Cairns MJ; Raabe EH; Vitanza NA; Hulleman E; Phoenix TN; Koschmann C; Alvaro F; Dayas CV; Tinkle CL; Wheeler H; Whittle JR; Eisenstat DD; Firestein R; Mueller S; Valvi S; Hansford JR; Ashley DM; Gregory SG; Kilburn LB; Nazarian J; Cain JE; Dun MD
J Clin Invest; 2024 Feb; 134(6):. PubMed ID: 38319732
[TBL] [Abstract][Full Text] [Related]
11. Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201.
Xin DE; Liao Y; Rao R; Ogurek S; Sengupta S; Xin M; Bayat AE; Seibel WL; Graham RT; Koschmann C; Lu QR
Neuro Oncol; 2024 Apr; 26(4):735-748. PubMed ID: 38011799
[TBL] [Abstract][Full Text] [Related]
12. Diffuse Intrinsic Pontine Glioma (DIPG): Breakthrough and Clinical Perspective.
Perrone MG; Ruggiero A; Centonze A; Carrieri A; Ferorelli S; Scilimati A
Curr Med Chem; 2021; 28(17):3287-3317. PubMed ID: 32767913
[TBL] [Abstract][Full Text] [Related]
13. Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis.
Borsuk R; Zhou L; Chang WI; Zhang Y; Sharma A; Prabhu VV; Tapinos N; Lulla RR; El-Deiry WS
Am J Cancer Res; 2021; 11(9):4607-4623. PubMed ID: 34659909
[TBL] [Abstract][Full Text] [Related]
14. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
[TBL] [Abstract][Full Text] [Related]
15. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.
Venneti S; Kawakibi AR; Ji S; Waszak SM; Sweha SR; Mota M; Pun M; Deogharkar A; Chung C; Tarapore RS; Ramage S; Chi A; Wen PY; Arrillaga-Romany I; Batchelor TT; Butowski NA; Sumrall A; Shonka N; Harrison RA; de Groot J; Mehta M; Hall MD; Daghistani D; Cloughesy TF; Ellingson BM; Beccaria K; Varlet P; Kim MM; Umemura Y; Garton H; Franson A; Schwartz J; Jain R; Kachman M; Baum H; Burant CF; Mottl SL; Cartaxo RT; John V; Messinger D; Qin T; Peterson E; Sajjakulnukit P; Ravi K; Waugh A; Walling D; Ding Y; Xia Z; Schwendeman A; Hawes D; Yang F; Judkins AR; Wahl D; Lyssiotis CA; de la Nava D; Alonso MM; Eze A; Spitzer J; Schmidt SV; Duchatel RJ; Dun MD; Cain JE; Jiang L; Stopka SA; Baquer G; Regan MS; Filbin MG; Agar NYR; Zhao L; Kumar-Sinha C; Mody R; Chinnaiyan A; Kurokawa R; Pratt D; Yadav VN; Grill J; Kline C; Mueller S; Resnick A; Nazarian J; Allen JE; Odia Y; Gardner SL; Koschmann C
Cancer Discov; 2023 Nov; 13(11):2370-2393. PubMed ID: 37584601
[TBL] [Abstract][Full Text] [Related]
16. Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma.
Duchatel RJ; Mannan A; Woldu AS; Hawtrey T; Hindley PA; Douglas AM; Jackson ER; Findlay IJ; Germon ZP; Staudt D; Kearney PS; Smith ND; Hindley KE; Cain JE; André N; La Madrid AM; Nixon B; De Iuliis GN; Nazarian J; Irish K; Alvaro F; Eisenstat DD; Beck A; Vitanza NA; Mueller S; Morris JC; Dun MD
Neurooncol Adv; 2021; 3(1):vdab169. PubMed ID: 34988452
[TBL] [Abstract][Full Text] [Related]
17. Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experience.
Mueller T; Laternser S; Guerreiro Stücklin AS; Gerber NU; Mourabit S; Rizo M; Rushing EJ; Kottke R; Grotzer M; Krayenbühl N; Nazarian J; Mueller S
Eur J Cancer; 2023 Jan; 178():171-179. PubMed ID: 36455411
[TBL] [Abstract][Full Text] [Related]
18. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies.
Persson ML; Douglas AM; Alvaro F; Faridi P; Larsen MR; Alonso MM; Vitanza NA; Dun MD
Neuro Oncol; 2022 Sep; 24(9):1408-1422. PubMed ID: 35481923
[TBL] [Abstract][Full Text] [Related]
19. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
[TBL] [Abstract][Full Text] [Related]
20. The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models.
de la Nava D; Ausejo-Mauleon I; Laspidea V; Gonzalez-Huarriz M; Lacalle A; Casares N; Zalacain M; Marrodan L; García-Moure M; Ochoa MC; Tallon-Cobos AC; Hernandez-Osuna R; Marco-Sanz J; Dhandapani L; Hervás-Corpión I; Becher OJ; Nazarian J; Mueller S; Phoenix TN; van der Lugt J; Hernaez M; Guruceaga E; Koschmann C; Venneti S; Allen JE; Dun MD; Fueyo J; Gomez-Manzano C; Gállego Pérez-Larraya J; Patiño-García A; Labiano S; Alonso MM
Neuro Oncol; 2024 Mar; ():. PubMed ID: 38554031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
